CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(02): 80-84
DOI: 10.4103/0971-5851.116183
ORIGINAL ARTICLE

Clinico-immunological response to intratumoral versus intravenous neoadjuvant chemotherapy in advanced pediatric solid malignancies

Vijayendra Kumar
Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Nandini Ramaswami
Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Anand Pandey
Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Ram Chandra Shukla
Department of Radiodiagnosis, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Maloy Ranjan Sen
Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Shiv Prasad Sharma
Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Dinesh Kumar Gupta
Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Ajay Narayan Gangopadhyay
Department of Pediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
› Author Affiliations

Abstract

Background: There is minimal literature on the use of intralesional chemotherapy in the pediatric age group. We undertook this present study to evaluate the two modalities (intratumoral and intravenous) of giving chemotherapy in terms of toxicity of chemotherapy, hematological parameters, efficacy of chemotherapy in reduction in volume of the tumor as well as resectability of tumor with special emphasis on immunological parameters. Materials and Methods: Advanced cases of Wilms′ tumor and Neuroblastoma were included in the study. Intratumoral chemotherapy was given through 25 G spinal needle under aseptic precautions and ultrasound guidance in the same dose as in systemic chemotherapy. Intravenous group was given chemotherapy in the usual way. Reassessment was carried out after every course of chemotherapy. Results: Group A included 16 cases of Wilms′ tumor and 6 cases of neuroblastoma. In group B, there were 14 cases of Wilms′ tumor and 8 of neuroblastoma. Vomiting, diarrhea, mucositis, and thrombophlebitis were more common in the intravenous group (P<0.05). The fall in Immunoglobulin A, Immunogloblulin G, Immunoglobulin M, and T-cell rosetting was more common in the intravenous group (P<0.05). Seventy percent of patients had completely resectable tumor at the end of 6 doses of intratumoral chemotherapy as compared to 50% resectability in the intravenous group (P<0.05). Conclusion: Intratumoral chemotherapy, besides causing less of the adverse effects and increasing the resecability rate, also causes less suppression of the immune system. This may be offered as an alternative safe and effective modality of treatment for advanced solid tumors.



Publication History

Article published online:
20 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics-2002. Pediatrics 2003;112:1215-30.
  • 2 Kusumakumary P, Jacob R, Jothirmayi R, Nair MK. Profile of pediatric malignancies: A ten year study. Indian Pediatr 2000;37:1234-8.
  • 3 Gupta DK, Sharma S, Agarwala S, Carachi R. Saga of Wilms′ tumor: Lessons learnt from the past. J Indian Assoc Pediatr Surg 2005;10:217-28.
  • 4 Ansfield FJ, Ramirez G, Davis HL Jr, Wirtanen GW, Johnson RO, Bryan GT, et al. Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer 1975;36:2413-7.
  • 5 Balch CM, Urist MM, McGregor ML. Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump. A feasibility study in 50 patients. Am J Surg 1983;145:285-90.
  • 6 Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, Anzai T, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 1985;3:1101-4.
  • 7 King ME, Pfeifle CE, Howell SB. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 1984;2:662-9.
  • 8 Breslow NE, Langholz B. Childhood cancer incidence: Geographical and temporal variations. Int J Cancer 1983;32:703-16.
  • 9 Green DM, Jaffe N. Wilms′ tumor-Model of a curable pediatric malignant solid tumor. Cancer Treat Rev 1978;5:143-72.
  • 10 Macmahon HE, Bedizel M, Ellis CA. Vincristine (leurocristine) sulfate in the treatment of children with metastatic Wilms′ tumor. Pediatric division, Southwest cancer chemotherapy group. Pediatrics 1963;32:880-7.
  • 11 Tagge EP, Thomas PB, Othersen HB Jr. Wilms′ tumor. In: Grosfeld JL, O′Neill JA Jr, Fonkalsrud EW, Coran AG, editors. Pediatric Surgery. 6 th ed. Philadelphia PA: Mosby Elsevier; 2006. p. 445-66.
  • 12 Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children′s Cancer Study Group Study. Clin Cancer Res 2005;11:5893-9.
  • 13 Groninger E, Meeuwsen-de Boar T, Koopmans P, Uges D, Sluiter W, Veerman A, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 2002;52:113-8.
  • 14 Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983;43:3417-21.
  • 15 Apte AV, Kumar V, Sharma SP, Arya NC, Gangopadhyay AN, Gupta DK, et al. How safe and effective is preoperative intratumoral chemotherapy in advanced Inoperable pediatric solid malignancies? J Indian Assoc Pediatr Surg 2001;6:119-24.
  • 16 Tournade MF, Com-Nougué C, Voûte PA, Lemerle J, de Kraker J, Delemarre JF, et al. Results of the Sixth International Society of Pediatric Oncology Wilms′ Tumor Trial and Study: A risk-adapted therapeutic approach in Wilms′ tumor. J Clin Oncol 1993;11:1014-23.
  • 17 Godzinski J, Tournade MF, De Kraker J, Ludwig R, Weirich A, Voute PA, et al. The role of preoperative chemotherapy in the treatment of nephroblastoma: The SIOP experience. Societe Internationale d′Oncologie Pediatrique. Semin Urol Oncol 1999;17:28-32.
  • 18 Kogan SJ, Marans H, Santorineau M, Schneider K, Reda E, Levitt SB. Successful treatment of renal vein and vena caval extension of nephroblastoma by preoperative chemotherapy. J Urol 1986;136:312-7.
  • 19 Bray GL, Pendergrass TW, Schaller RT Jr, Kiviat N, Beckwith JB. Preoperative chemotherapy in the treatment of Wilms′ tumor diagnosed with the aid of fine needle aspiration biopsy. Am J Pediatr Hematol Oncol 1986;8:75-8.
  • 20 Ritchey ML, Pringle KC, Breslow NE, Takashima J, Moksness J, Zuppan CW, et al. Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3. Ann Surg 1994;220:683-90.
  • 21 Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 2002;54:159-80.
  • 22 Gangopadhyay AN, Rajeev R, Sharma SP, Upadhyaya VD, Arya NC, Kumar V, et al. Anterior intratumoural chemotherapy: A newer modality of treatment in advanced solid tumours in children. Asian J Surg 2008;31:225-9.